Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Mark W, Albers"'
Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
Autor:
Ibai Diez, Laura Ortiz-Terán, Thomas S. C. Ng, Mark W. Albers, Gad Marshall, William Orwig, Chan-mi Kim, Elisenda Bueichekú, Victor Montal, Jonas Olofsson, Patrizia Vannini, Georges El Fahkri, Reisa Sperling, Keith Johnson, Heidi I. L. Jacobs, Jorge Sepulcre
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract The direct access of olfactory afferents to memory-related cortical systems has inspired theories about the role of the olfactory pathways in the development of cortical neurodegeneration in Alzheimer’s disease (AD). In this study, we used
Externí odkaz:
https://doaj.org/article/53baab9f774f44ed85ed879dfc0ad4b7
Autor:
Marie-Laure Charpignon, Bella Vakulenko-Lagun, Bang Zheng, Colin Magdamo, Bowen Su, Kyle Evans, Steve Rodriguez, Artem Sokolov, Sarah Boswell, Yi-Han Sheu, Melek Somai, Lefkos Middleton, Bradley T. Hyman, Rebecca A. Betensky, Stan N. Finkelstein, Roy E. Welsch, Ioanna Tzoulaki, Deborah Blacker, Sudeshna Das, Mark W. Albers
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Previous observational studies of the diabetes drugs metformin vs. sulfonylureas have yielded mixed results about whether metformin reduces the risk of dementia, relative to the sulfonylureas. Here, the authors apply a novel competing risks approach
Externí odkaz:
https://doaj.org/article/6c6653ae33484933bc4f68d1094c553c
Autor:
Steve Rodriguez, Clemens Hug, Petar Todorov, Nienke Moret, Sarah A. Boswell, Kyle Evans, George Zhou, Nathan T. Johnson, Bradley T. Hyman, Peter K. Sorger, Mark W. Albers, Artem Sokolov
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have provided largely negative results, so far. Here, the authors present a machine learning framework that quantifies potential associations between the pathology of AD severity an
Externí odkaz:
https://doaj.org/article/93e763bd3055417ea9c559a7b6fa24d5
Autor:
Liliana, Ramirez-Gomez, Mark W, Albers, Ana, Baena, Clara, Vila-Castelar, Joshua T, Fox-Fuller, Justin, Sanchez, Felipe, Jain, Alefiya D, Albers, Francisco, Lopera, Yakeel T, Quiroz
Publikováno v:
J Alzheimers Dis
Background: Olfactory dysfunction is one of the earliest signs of Alzheimer’s disease (AD), highlighting its potential use as a biomarker for early detection. It has also been linked to progression from mild cognitive impairment (MCI) to dementia.
Autor:
Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David A. Gudis, Antje Haehner, Thomas S. Higgins, Claire Hopkins, Caroline Huart, Thomas Hummel, Kawinyarat Jitaroon, Robert C. Kern, Ashoke R. Khanwalkar, Masayoshi Kobayashi, Kenji Kondo, Andrew P. Lane, Matt Lechner, Donald A. Leopold, Joshua M. Levy, Michael J. Marmura, Lisha Mclelland, Takaki Miwa, Paul J. Moberg, Christian A. Mueller, Sagar U. Nigwekar, Erin K. O'Brien, Teodor G. Paunescu, Robert Pellegrino, Carl Philpott, Jayant M. Pinto, Evan R. Reiter, David R. Roalf, Nicholas R. Rowan, Rodney J. Schlosser, James Schwob, Allen M. Seiden, Timothy L. Smith, Zachary M. Soler, Leigh Sowerby, Bruce K. Tan, Andrew Thamboo, Bozena Wrobel, Carol H. Yan
Publikováno v:
International forum of allergy & rhinology, Vol. 12, no.4, p. 327-680 (2022)
Background: The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this lite
Autor:
Bradley T. Hyman, Nathan T. Johnson, Sarah A. Boswell, Mark W. Albers, Kyle Evans, George Zhou, Artem Sokolov, Clemens B. Hug, Steven Rodriguez, Peter K. Sorger, Nienke Moret, Petar Todorov
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication
Autor:
Marie-Laure Charpignon, Kyle Evans, Steven Rodriguez, Mark W. Albers, B. Zhang, Yi-Han Sheu, Deborah Blacker, Bella Vakulenko-Lagun, Ioanna Tzoulaki, Rebecca A. Betensky, Saumya Das, R. E. Welsch, Sarah A. Boswell, B. T. Hyman, A. Sololov, S. N. Finkelstein, C. Magdomo, Bowen Su, Lefkos T. Middleton, M. Somai
Metformin, an antidiabetic drug, triggers anti-aging cellular responses. Aging is the principal risk factor for dementia, but previous observational studies of the diabetes drugs metformin vs. sulfonylureas have been mixed. We tested the hypotheses t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acfec084548364c3449c4c724339daba
https://doi.org/10.1101/2021.08.10.21261747
https://doi.org/10.1101/2021.08.10.21261747
Autor:
Elena Ratti, Alexis C. Gomez, Mark W. Albers, Matthew P. Frosch, Isabel Costantino, Steven Rodriguez, Eric B. Benz, Asli Sahin, Peter K. Sorger, Hawra Al-Lawati, Michael E. Talkowski, Benjamin R. Schrank, Bradley T. Hyman, Darian Fard, Alefiya Dhilla Albers, Luxiang Cao, Kyle Evans, Merit Cudkowicz
Publikováno v:
Science Translational Medicine. 13
Triggers of innate immune signaling in the CNS of patients with amyotrophic lateral sclerosis and frontotemporal degeneration (ALS/FTD) remain elusive. We report the presence of cytoplasmic double-stranded RNA (cdsRNA), an established trigger of inna
Autor:
Bradley T. Hyman, Robert A. Rissman, Lore Gruenbaum, Mark W. Albers, Lin Lin, Raibatak Das, Douglas A. Lauffenburger, Hafiz Mohmmadabdul, Fei Hua, John M. Burke, Joshua F. Apgar, Lucia Wille, Kumpal Madrasi
Publikováno v:
Wiley
Alzheimers Dement
Alzheimers Dement
Introduction Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2926739c0e07a09427f41ae948a13936
https://hdl.handle.net/1721.1/135639
https://hdl.handle.net/1721.1/135639
Autor:
Bradley T. Hyman, Alefiya Dhilla Albers, Mark W. Albers, Joseph J. Locascio, Teresa Gomez-Isla, Deborah Blacker, Abigail C Keim, Sudeshna Das, Camille Cunin
Publikováno v:
Alzheimer's & Dementia. 16